209 related articles for article (PubMed ID: 15364627)
21. Myths and facts...about ephedrine use.
Munson BL
Nursing; 2003 Apr; 33(4):81. PubMed ID: 12722724
[No Abstract] [Full Text] [Related]
22. The FDA, regulation, and the risk of stroke.
Fleming GA
N Engl J Med; 2000 Dec; 343(25):1886-7. PubMed ID: 11117982
[No Abstract] [Full Text] [Related]
23. Ephedra in perspective--a current review.
Abourashed EA; El-Alfy AT; Khan IA; Walker L
Phytother Res; 2003 Aug; 17(7):703-12. PubMed ID: 12916063
[TBL] [Abstract][Full Text] [Related]
24. Psychiatric effects of ephedra: addiction.
Miller SC
Am J Psychiatry; 2005 Nov; 162(11):2198. PubMed ID: 16263877
[No Abstract] [Full Text] [Related]
25. The new law: public law 109-462 for dietary supplements.
Jiang T
Eur J Clin Nutr; 2009 Feb; 63(2):300. PubMed ID: 17851457
[No Abstract] [Full Text] [Related]
26. Medicolegal issues and ergogenic aids: trade, tragedy, and public safety, the example of ephedra and the Dietary Supplement Health and Education Act.
Phillips GC
Curr Sports Med Rep; 2004 Aug; 3(4):224-8. PubMed ID: 15231227
[TBL] [Abstract][Full Text] [Related]
27. Editorial: assessing the safety of dietary supplements.
Bent S
Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):958-60. PubMed ID: 17705239
[No Abstract] [Full Text] [Related]
28. Protecting consumers in the wake of the U.S. Dietary Supplement Health and Education Act.
Foote JC
J Allied Health; 2007; 36(1):57-60. PubMed ID: 17425193
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder.
Newcorn JH; Donnelly C
Mt Sinai J Med; 2009 Apr; 76(2):198-203. PubMed ID: 19306385
[No Abstract] [Full Text] [Related]
30. Dangerously revved. Ephedrine misuse poses health hazards.
Jones TL
Tex Med; 1996 May; 92(5):52-3. PubMed ID: 8775849
[No Abstract] [Full Text] [Related]
31. The need for regulation of dietary supplements--lessons from ephedra.
Fontanarosa PB; Rennie D; DeAngelis CD
JAMA; 2003 Mar; 289(12):1568-70. PubMed ID: 12672775
[No Abstract] [Full Text] [Related]
32. Are serious adverse cardiovascular events an unintended consequence of the Dietary Supplement Health and Education Act of 1994?
Lindsay BD
Mayo Clin Proc; 2002 Jan; 77(1):7-9. PubMed ID: 11795250
[No Abstract] [Full Text] [Related]
33. Challenges in collecting, accessing and evaluating post market surveillance AERS in patients receiving dietary supplements.
Kingston R
Thromb Res; 2005; 117(1-2):137-44; discussion 145-51. PubMed ID: 16139875
[No Abstract] [Full Text] [Related]
34. "Tag--we're it".
Czap A
Altern Med Rev; 2003 May; 8(2):104. PubMed ID: 12777156
[No Abstract] [Full Text] [Related]
35. The trouble with fat-burner pills.
Smith IK
Time; 2001 Aug; 158(8):66. PubMed ID: 11534484
[No Abstract] [Full Text] [Related]
36. Ephedrine abuse among 36 female weightlifters.
Gruber AJ; Pope HG
Am J Addict; 1998; 7(4):256-61. PubMed ID: 9809129
[TBL] [Abstract][Full Text] [Related]
37. Academic perspectives on dietary supplements use: the need for new guidelines.
Grollman AP
Thromb Res; 2005; 117(1-2):185-92; discussion 201-7. PubMed ID: 16143370
[No Abstract] [Full Text] [Related]
38. US Senate passes FDA Revitalization Act.
Guthrie P
CMAJ; 2007 Jul; 177(1):23. PubMed ID: 17606930
[No Abstract] [Full Text] [Related]
39. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation.
Struve CT
Yale J Health Policy Law Ethics; 2005; 5(2):587-669. PubMed ID: 16052895
[No Abstract] [Full Text] [Related]
40. "All but death, can be adjusted". Ma Huang (ephedrine) adversities.
Mack RB
N C Med J; 1997; 58(1):68-70. PubMed ID: 9019118
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
